Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
Maria Vittoria Dieci(Istituto Oncologico Veneto), Valentina Guarneri(Istituto Oncologico Veneto), Enrico Cumerlato(University of Padua), Fabio Canino(University of Modena and Reggio Emilia), Federica Miglietta(University of Padua), Luisa Carbognin(Agostino Gemelli University Polyclinic), Emilio Bria(Università Cattolica del Sacro Cuore), Antonio Tornincasa(University of Modena and Reggio Emilia), Giovanni Zarrilli(University of Padua), Matteo Fassan(University of Padua), Silvia Michieletto(Istituto Oncologico Veneto), Lucia Trudu(University of Modena and Reggio Emilia), Giovanna Garufi(Agostino Gemelli University Polyclinic), Marcello Mele(University of Pisa), Ottavia Amato, Carlo Alberto Giorgi(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico), Diana Giannarelli(Agostino Gemelli University Polyclinic), Davide Massa(University of Padua), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Elisa Genovesi(University of Padua)
Cited by 9
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290